New & Notable
GLP-1 drugs primed for FDA approval in 2026
With Pharma titans Eli Lilly and Novo Nordisk continuing to duke it out for control of the GLP-1 market, both are seeking FDA approval for new drugs this year.
Novo's Wegovy pill hits the market with a $149 cash-pay price
Novo Nordisk has launched oral Wegovy in the U.S., with cash-pay pricing starting at $149 per month for the lowest doses and ranging up to $299 for higher doses.
The FDA approves the first GLP-1 weight loss pill
The FDA has approved the oral version of Novo Nordisk's popular injectable obesity drug Wegovy, making it the first GLP-1 pill cleared for weight loss.
Novo submits its next-gen obesity drug for FDA approval
Novo Nordisk has filed for FDA approval of its next-generation, combination obesity drug, CagriSema, with a review expected next year.
FDA approves first drug in National Priority Voucher program
— BioPharma DiveHealthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Ascletis announces phase 2 data for its oral GLP-1 candidate
China's Ascletis Pharma reported a 7.7% placebo-adjusted weight loss for the highest dose of its oral GLP-1 drug candidate, ASC30, in a U.S.-based, phase 2 trial.
-
Eli Lilly lowers Zepbound costs amid rising calls for affordability
Lilly cuts prices for its weight loss drug Zepbound as the World Health Organization issues its first global GLP-1 obesity guidelines, urging expanded access and affordability.
-
WHO releases its first-ever GLP-1 weight-loss drug guidelines
GLP-1 drugs approved for weight loss can be combined with behavioral therapy as part of a long-term strategy in adults, the WHO says in new guidance.
-
Novo Nordisk's amycretin shows competitive phase 2 weight loss
After yesterday's setback, Novo Nordisk released mid-stage data showing oral and injectable amycretin led to 7.6% and 11.9% placebo-adjusted weight loss, respectively, in patients with type 2 diabetes.
-
Consumer confusion fuels risky online drug purchases, survey finds
Due to widespread misunderstandings, many U.S. adults are buying drugs, especially GLP-1 products, from online, unlicensed sellers, a new survey reveals.
-
Wegovy linked to liver health benefits at low levels of weight loss
Wegovy may improve liver injury and scarring in adults with MASH and moderate-to-severe fibrosis, even without significant weight loss, data shows.
Features
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.
-
Expanding clinical trial access through technology, support
Systemic barriers continue to restrict clinical trial access, but when deployed correctly, technology can provide patient–provider support and close interoperability gaps.
-
Will the FDA's green list end illegal GLP-1 compounding?
The FDA recently created a green list to regulate imported GLP-1 drug ingredients, yet experts say that weak enforcement could allow illegal compounding operations to continue.
-
Using AI to identify, expose online drug counterfeiters
Pharmaceutical companies are leveraging AI's advanced detection and enforcement tools to combat the online counterfeit drug market, protecting brand integrity and consumer safety.